Concord Biotech Ltd

Concord Biotech Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Concord Biotech Ltd

₹ 1,272 6.31%
09 Jun - close price
concordbiotech.com BSE: 543960 NSE: CONCORDBIO
About

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Key Points

Business Profile[1]
Concord Biotech is a pharmaceutical company headquartered in Ahmedabad, Gujarat, specializing in Active Pharmaceutical Ingredients (APIs) and formulations. The company is engaged in development and manufacturing of niche fermentation-based APIs and finished dosage formulations for domestic and international markets.

Website BSE NSE
  • Market Cap ₹ 13,300 Cr.
  • Current Price ₹ 1,272
  • High / Low ₹ 2,150 / 987
  • Stock P/E 50.5
  • Book Value ₹ 193
  • Dividend Yield 0.84 %
  • ROCE 18.2 %
  • ROE 13.8 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 28.2%

Cons

  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Company has high debtors of 159 days.
  • Working capital days have increased from 243 days to 369 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty500 Shariah BSE 250 SmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
273 195 262 241 319 216 310 244 430 204 247 278 326
146 123 147 135 187 135 176 146 241 143 159 179 208
Operating Profit 127 72 116 106 132 81 134 98 189 61 88 98 118
OPM % 47% 37% 44% 44% 41% 38% 43% 40% 44% 30% 36% 35% 36%
12 13 8 11 11 12 10 17 9 15 16 7 15
Interest 1 1 1 0 0 0 0 0 0 0 0 0 0
Depreciation 14 13 13 14 14 13 13 13 15 18 18 19 20
Profit before tax 124 71 110 103 129 80 130 101 184 59 86 86 114
Tax % 26% 23% 26% 25% 26% 25% 27% 25% 24% 25% 26% 26% 22%
91 54 81 78 95 60 96 76 140 44 63 64 88
EPS in Rs 8.75 5.21 7.74 7.41 9.08 5.70 9.15 7.26 13.42 4.21 6.08 6.16 8.49
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
512 616 713 853 1,017 1,200 1,055
308 289 443 509 585 694 687
Operating Profit 205 327 270 344 432 506 367
OPM % 40% 53% 38% 40% 42% 42% 35%
32 14 23 37 37 44 52
Interest 1 1 6 5 3 1 0
Depreciation 21 28 50 54 54 54 74
Profit before tax 214 313 238 322 413 495 345
Tax % 21% 25% 26% 25% 25% 25% 25%
169 235 175 240 308 372 259
EPS in Rs 177.81 247.44 183.93 22.95 29.45 35.52 24.94
Dividend Payout % 22% 0% 3% 30% 30% 25% 30%
Compounded Sales Growth
10 Years: %
5 Years: 11%
3 Years: 7%
TTM: -12%
Compounded Profit Growth
10 Years: %
5 Years: 3%
3 Years: 4%
TTM: -26%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -39%
Return on Equity
10 Years: %
5 Years: 18%
3 Years: 18%
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 10 10 10 10 10 10 10
Reserves 761 990 1,094 1,280 1,516 1,802 2,007
52 86 62 32 10 3 2
118 97 147 192 164 219 215
Total Liabilities 941 1,183 1,313 1,514 1,701 2,034 2,235
240 546 573 593 575 795 793
CWIP 141 18 74 173 211 51 78
Investments 199 141 74 137 246 335 487
361 477 592 611 668 854 876
Total Assets 941 1,183 1,313 1,514 1,701 2,034 2,235

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
155 167 207 246 265 245 267
-114 -195 -112 -158 -155 -160 -143
-43 31 -100 -85 -99 -99 -113
Net Cash Flow -1 3 -4 3 12 -14 11
Free Cash Flow -1 -38 52 101 180 134 172
CFO/OP 100% 74% 99% 92% 85% 70% 100%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 131 105 119 117 125 159 159
Inventory Days 312 503 434 430 331 286 485
Days Payable 201 152 185 190 150 135 151
Cash Conversion Cycle 242 456 368 357 306 310 493
Working Capital Days 159 177 161 152 166 193 369
ROCE % 32% 21% 26% 28% 28% 18%

Insights

In beta
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2025
Fermentation Capacity - Total
m3

Log in to view insights

Please log in to see hidden values.

Login
R&D Spend as % of Sales
%
Unit I (Dholka) - Fermentation Capacity Utilization
%
Export Presence (Countries)
Number
Total Generic APIs in Portfolio
Number
Unit II (Valthera) - Formulation Capacity Utilization
%
Unit III (Limbasi) - Fermentation Capacity Utilization
%
Cumulative DMFs Filed
Number
Global Market Share - Cyclosporine (Volume)
%
Global Market Share - Tacrolimus (Volume)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08% 44.08%
7.30% 7.00% 6.49% 7.11% 8.10% 8.33% 9.35% 9.10% 8.03% 7.58% 7.79%
8.12% 8.40% 8.41% 10.35% 9.89% 9.65% 9.16% 8.85% 9.55% 9.58% 9.22%
40.50% 40.52% 41.03% 38.46% 37.95% 37.93% 37.41% 37.94% 38.32% 38.75% 38.90%
No. of Shareholders 1,00,92787,48683,29680,73784,29882,00481,21982,04582,65081,81582,249

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls